Lonza Group stock
Price history
+23.84% over the period1 year: from CHF 539.40 (November 17, 2025) to CHF 668.00 (November 17, 2026), +23.84%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | CHF 668.00 |
| October 30, 2026 | CHF 644.20 |
| September 30, 2026 | CHF 575.20 |
| August 31, 2026 | CHF 576.60 |
| July 31, 2026 | CHF 562.20 |
| June 30, 2026 | CHF 545.80 |
| May 29, 2026 | CHF 500.40 |
| April 30, 2026 | CHF 479.20 |
| March 31, 2026 | CHF 504.80 |
| February 27, 2026 | CHF 536.20 |
| January 30, 2026 | CHF 525.00 |
| December 30, 2025 | CHF 537.80 |
| November 28, 2025 | CHF 550.00 |
| November 17, 2025 | CHF 539.40 |
At a glance
The company
Contract development and manufacturing organization providing CDMO services for biologics, advanced synthesis and specialized modalities to pharma and biotech companies worldwide
Latest results
Quarter to June 30, 2026 · EPS CHF 8.12 (estimate CHF 8.24)
TickerLandia's take on Lonza Group
- Pricier than usual relative to earnings: P/E on the latest fiscal year 51 vs a median of 40 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 44 vs 31 (+43%) in a group of 10.
- Strong point: Market momentum (84/100 in its group). Weak point: Earnings stability (42/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.87% from the 52-week high
Analysts · 24 analysts
Average targetCHF 719.65+8.54% vs. price
Buy 21 · Hold 3 · Sell 0 · Buy
TickerLandia Fingerprint: Lonza Group
Compared with similar companies: very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh70
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 44.5 77 Forward P/E 29.9 82 EV/EBITDA 21.0 54 Price/book 5.77 63 Price/sales 6.83 72 Profitabilityaverage46
How much it earns on revenue and capital.
Metric Value Position in group Net margin −1.6% 13 Gross margin 37.1% 39 ROE 12.9% 57 ROA 5.4% 43 Operating margin 23.5% 76 Earnings stabilityaverage42
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.6% 65 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 19 Growthhigh64
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +39.20% 80 Revenue growth (year over year) +11.20% 72 Average revenue growth (3 years) +1.62% 39 Financial strengthaverage53
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.85 50 Debt/equitycounts in reverse: lower means more financial strength 0.51 61 Current ratio 1.66 46 Interest coverage 8.32 56 Dividendaverage56
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 27 years 79 Dividend yield 0.7% 37 Payout ratio 33.1% 53 Market momentumvery strong84
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +12.52% 85 Relative strength (6 months) +23.89% 91 Distance from 200-day average +23.21% 92 1-year return +23.11% 66 Risklow37
How much the price swings.
Metric Value Position in group Volatility (60 days) 21.0% 23 Beta (1 year) 0.91 63 Maximum drawdown (12 months) 17.5% 24
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Lonza Group is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Lonza Group's P/E today is 51.5, above the median of its last 10 fiscal years (40.3; between 27.1 and 84.2 from 2016 to 2025). Lonza Group's P/E (trailing 12 months): 43.9, +43% against the median of a group of 10 similar companies (30.8).
Compared with 10 similar companies
| Metric | Lonza Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 43.9 | High | |
| Forward P/E | 29.5 | High | |
| Operating margin | 23.5% | Middle | |
| ROE | 12.9% | Middle | |
| Debt/equity | 0.51 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Lonza Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
CHF 3.37B
Latest quarter · Q2 2026
Net income
CHF 591M
Latest quarter · Q2 2026
Quarterly net margin
17.5%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 46.31B
- P/E
- 43.9
- EPS
- CHF 15.09
- Volume
- 117.67K
- Daily trading
- €99.24M
- Dividend yield
- 0.75%
- Last ex-dividend on May 12, 2026
How Lonza Group is changing
All resultsRevenue grew 7.7% a year on average over the last 5 years
Less cash than profit: free cash flow equal to -52% of net income
Shares outstanding down 6.3% in 5 years
Returns
Lonza Group returns with dividends
CHF 1,000 invested in Lonza Group 5 years ago, on November 17, 2021, would be worth CHF 936 today with dividends reinvested: −6.35% in total, −1.30% per year. On price alone it would be CHF 902 (−9.75%).
| Period | Lonza Group | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +8.94% | +4.53% | CHF 1,089 |
| 6 months | +41.24% | +13.61% | CHF 1,412 |
| Year to date | +24.21% | +13.20% | CHF 1,242 |
| 1 year | +25.14% | +19.22% | CHF 1,251 |
| 3 years | +92.95% | +39.88% | CHF 1,929 |
| 5 years | −6.35% | +19.20% | CHF 936 |
| 10 years | +334.84% | +88.57% | CHF 4,348 |
Over the last 6 months it has done better than 63% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Lonza Group: technical analysis
Lonza Group is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 15.5% below its all-time closing high (CHF 784.60, September 6, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 67
- Between 30 and 70
- vs 200-session average
- +21.73%
Support and resistance
Price areas where Lonza Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 663.00
- SupportCHF 593.53−10.48%3 touches, last on October 6, 2026
- SupportCHF 582.13−12.20%3 touches, last on August 11, 2026
- SupportCHF 554.60−16.35%3 touches, last on October 2, 2026
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 0.91
- Volatility (60 sessions, annualised)
- 21.1%
- Largest fall in the last year
- −17.52%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Lonza Group: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Lonza Group has been July: +4.63% on average, positive in 20 years out of 27. The weakest has been August: −0.69% on average, positive in 14 years out of 27. November, the current month, has been positive in 13 years out of 26 (+0.70% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.52% | +0.21% | 16 of 27 |
| February | +1.32% | +0.67% | 17 of 27 |
| March | +1.47% | +1.09% | 15 of 27 |
| April | +0.71% | +1.63% | 15 of 27 |
| May | +0.31% | +1.71% | 15 of 27 |
| June | −0.45% | −0.58% | 11 of 27 |
| July | +4.63% | +3.61% | 20 of 27 |
| August | −0.69% | +0.11% | 14 of 27 |
| September | −0.50% | −0.36% | 12 of 27 |
| October | +0.17% | +4.33% | 18 of 27 |
| November | +0.70% | −0.24% | 13 of 26 |
| December | +0.68% | +1.73% | 16 of 27 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Lonza Group and its competitors
Contract development and manufacturing for pharma and biotech companies forms the core of Lonza Group AG, which serves clients in Europe, North and Central America, Latin America, Asia, Australia and New Zealand. Its Integrated Biologics unit covers biologics services from clinical development through drug substance and drug product manufacturing, while Advanced Synthesis makes antibody-drug conjugates, related bioconjugates and potent active ingredients. The Specialized Modalities unit spans cell and gene, microbial, bioscience and mRNA technologies.
- Headquarters
- Basel, Switzerland
- Employees
- 20,141
- Founded
- 1897
- Chief executive
- Wolfgang Wienand
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Lonza GroupLONN | $55.11B | 23.5% | 43.9 | +41.24% |
| Eurofins ScientificERF | $16.53B | 14.1% | 30.5 | +44.16% |
| bioMérieuxBIM | $11.7B | 16.0% | 23.2 | +26.52% |
| QiagenQIA | $10.3B | 26.7% | 27.3 | +58.79% |
| DiaSorinDIA | $4.56B | 22.3% | 31.0 | +16.24% |
| DiagnostykaDIA | $1.29B | 14.9% | 20.3 | −5.09% |
Same industry or related industries, similar size. Compare Lonza Group with its competitors · Full profile
